FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burde	en								
hours per response:	0.5								

	Check this box if no longer subject to								
\neg	Section 16. Form 4 or Form 5								
J	obligations may continue. See								
	Instruction 1(b).								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							311 00(1.)		invesiment C	, opa	7101	0. 20.0							
1. Name and Address of Reporting Person* <u>COX GEOFFREY F</u>					2. Issuer Name and Ticker or Trading Symbol Aviragen Therapeutics, Inc. [AVIR]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
											X Directo	or		10% Ov	vner				
(Last) (First) (Middle) 2500 NORTHWINDS PARKWAY					Date o		Trans	saction (Mont	h/Day/Ye	ear)		Officer below)	(give title		Other (s below)	specify			
CTE 100																			
STE 100					4. 1	f Ame	ndment, [Date (of Original Fil	ed (Mont	th/Da	6. Ir	6. Individual or Joint/Group Filing (Check Applicable						
					-								Line	•					
(Street)														X Form f	iled by One	e Repo	orting Perso	n	
ALPHA	RETTA (GA 	30009		_									Form f Persor		re thar	One Repo	rting	
(City)	(:	State)	(Zip)																
		Tak	ole I - Nor	ı-Deriv	vativ	e Se	curities	s Ac	quired, D	ispose	ed o	f, or Ber	neficial	y Owned	l				
1. Title of Security (Instr. 3) 2. Transar Date (Month/D				Execution Date			Code (Instr. 5)				d (A) or tr. 3, 4 and	Benefici Owned I	es Fo ally (D) Following (I)	Form (D) o	Ownership rm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code V	Amo	ount	t (A) or P		Reporte Transac (Instr. 3	ction(s)			(Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	xecution Date, Tr		ction Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A) (D) Exercisable Expiration Date Title Shares												
Stock Option (Right to Buy)	\$0.49	05/18/2017			A		20,000		05/18/2018	05/18/2	2027	Common Stock	20,000	\$0.49	103,33	32	D		

Explanation of Responses:

/s/ Mark Colonnese attorney-in-05/22/2017 fact for Geoffrey F. Cox

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).